Comparative Effectiveness Will Likely Move To Cost Matters, Speakers Say
This article was originally published in The Gray Sheet
Executive Summary
Industry efforts to restrict comparative effectiveness research from morphing into outright cost comparisons might be a losing battle, some speakers at last week's AdvaMed meeting suggested
You may also be interested in...
CMS Plans Cost-Cutting Revamp Of Physician Fee Schedule
Faced with a fast-depleting Medicare Trust Fund, CMS officials say a sense of urgency underlies their efforts to find rational ways to cut payments in the Physician Fee Schedule
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”